Between 2022 and 2035, the bioavailability enhancement services market will see an 11 percent compound annual growth rate, a report has predicted.
List view / Grid view
With the appropriate formulation strategies, the challenges around poorly soluble compounds can indeed be overcome. Reducing development time and ultimately speeding up the route to market.
22 March 2021 | By
Eurofins CDMO is a leading global Contract Development and Manufacturing Organization (CDMO) that provides clients with APIs / Drug Substance and Drug Product development for biologicals and small molecules. Science is our fondation and allows us to support small and major biopharmaceutical companies. Our sustainable and flexible methods help them…
The commercial brand for Eurofins Alphora and Eurofins Amatsigroup is now Eurofins CDMO (Contract Development Manufacturing Organization).
Eurofins CDMO provides full range of drug development and manufacturing services from formulation screening and development, analytical development, stability studies and pre-clinical safety assessment studies to sterile and non-sterile manufacturing, IND/ IMPD and NDA/ CTD services, as well as clinical trial material including packaging and logistics.
Eurofins CDMO provides a full suite of drug development services encompassing development of the bioprocesses, formulation screening, analytical development, pre-clinical testing, sterile and non-sterile bio-manufacturing of clinical trial batches and orphan drugs.
Eurofins CDMO provides a wide range of aseptic processing services for all drug product configurations with flexibility to accommodate a wide range of compounds, primary packaging systems, batch sizes and fill volumes to help develop your Active Pharmaceutical Ingredient or bulk product into Finished Dosage Forms for use in clinical…